A Case of Slowly Progressive Type 1 Diabetes with Insulin Independence Maintained for 10 Years with α-glucosidase Inhibitor Monotherapy
-
- Munakata Yuichiro
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Yamada Tetsuya
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Takahashi Kazuma
- Division of Diabetes and Metabolism, Department of Internal Medicine, Iwate Medical University School of Medicine, Japan
-
- Tsukita Sohei
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Takahashi Kei
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Sawada Shojiro
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Imai Junta
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Ishigaki Yasushi
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Oka Yoshitomo
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
-
- Katagiri Hideki
- Department of Diabetes and Metabolism, Tohoku University Hospital, Japan
Bibliographic Information
- Other Title
-
- A case of slowly progressive type 1 diabetes with insulin independence maintained for 10 years with alpha-glucosidase inhibitor monotherapy
Search this article
Abstract
Slowly Progressive Type 1 Diabetes (SPT1D) is characterized by the absence of insulin dependence at the onset of diabetes and persistent detection of islet cell autoantibodies. These patients with high titers of glutamic acid decarboxylase autoantibodies (GADA) are known to progress to insulin dependence within several years. Low-dose insulin injections have been reported to prevent or delay the decline of insulin secretion in SPT1D patients. We experienced the case of an SPT1D patient with preserved endogenous insulin secretion and good glycemic control achieved with α-glucosidase inhibitor (α-GI) treatment alone for 10 years despite having continuously elevated GADA titers. The details of this case suggest that α-GI treatment might have preventive effects on SPT1D progression.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 51 (24), 3391-3394, 2012
The Japanese Society of Internal Medicine
